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Abstract 
Metastasis accounts for most of cancer-related deaths. Paracrine signaling between tumor cells 
and the stroma induces changes in the tumor microenvironment required for metastasis. 
Transcription factor c-Myb was associated with breast cancer (BC) progression but its role in 
metastasis remains unclear. Here we show that increased c-Myb expression in BC cells inhibits 
spontaneous lung metastasis through impaired tumor cell extravasation. On contrary, BC cells 
with increased lung metastatic capacity exhibited low c-Myb levels. We identified a specific 
inflammatory signature, including Ccl2 chemokine; that was expressed in lung metastatic cells 
but was suppressed in tumor cells with higher c-Myb levels. Tumor cell-derived Ccl2 expression 
facilitated lung metastasis and rescued trans-endothelial migration of c-Myb overexpressing cells. 
Clinical data show that the identified inflammatory signature, together with a MYB expression, 
predicts lung metastasis relapse in BC patients. These results demonstrate that the c-Myb-
regulated transcriptional program in BCs results in a blunted inflammatory response and 
consequently suppresses lung metastasis.  
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Introduction 
Breast cancer (BC) 5 year disease-free survival rate is about 90% in patients with 
localized disease, but only 25% of patients with metastasis will survive 5 years from the date of 
diagnosis.1 While many therapies contribute to prolonged patients survival, the identification of 
metastatic mediators driving tissue-specific metastasis remains the major objective for further 
therapeutic development. Distribution of BC metastasis to the bones, brain, lungs and liver is a 
non-random process and each tumor type manifests a specific pattern of metastatic progression to 
distant organs.2,3 Metastasis comprises multiple steps including the tumor cell (TC) escape from 
primary location, survival in the circulation, seeding to distant sites and initiation of the growth at 
secondary sites. Circulating TCs engage with the endothelial cells in the vasculature, extravasate 
into distant organs and adopt the environment permissible for tumor growth. Tumor cells seeding 
and tissue colonization of distant organs are considered to be the rate-limiting step defining 
metastasis. 
The c-Myb protein encoded by MYB/Myb gene is an essential transcriptional regulator for 
the maintenance of stem cells in bone marrow, colon epithelia, and neurogenic niches in an adult 
brain.4 Furthermore, normal hematopoiesis and cell lineage commitment are dependent on MYB 
function.5 The c-Myb binds to the specific sequence t/cAACt/gG, known as a Myb-binding site 
(MBS), within the control regions of target genes.4 The Myb-targeted genes are associated with 
cell proliferation, differentiation and apoptosis. However, c-Myb regulates different genes in 
distinct cell types, suggesting a context-specific regulation of transcription.6,7 
The pioneering research on MYB focused on its oncogenic function in leukemia, but MYB 
expression has later been also linked to epithelial cancers, particularly breast and colon cancers.4 
The presence of c-Myb is considered to be essential for the proliferation of ER-positive BC cells 
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and also a prerequisite for mammary carcinogenesis in murine models.8,9 However, clinical data 
show that high MYB levels are associated with good prognosis for BC patients.10-12 One 
possibility to explain these contradictory findings is that c-Myb-driven proliferation of ER-
positive BC tumors might be more responsive to cytotoxic drug treatment.13 Recently, we showed 
that c-Myb expression is inversely correlated with distant metastases in CRC patients and 
prevents murine mammary tumors to disseminate to lungs.14,15 However, the molecular 
mechanism how c-Myb contributes to metastasis remains unclear. 
In this study, we used complementary strategies of c-Myb overexpression and in vivo 
selection of metastatic cells to evaluate transcriptional program regulated by c-Myb in BC cells. 
We identified an inflammatory signature required for pulmonary BC metastasis, which is 
suppressed by c-Myb; that may serve as a clinical predictor of tissue-specific relapse in BCs 
patients. 
 
 
Results 
Myb expression inhibits breast cancer lung metastasis 
Overexpression of transcription factor (TF) Myb in murine mammary cancer cells 4T1 
hinders spontaneous lung metastasis.15 To analyze the mechanism of the c-Myb activity, two 
independent clones (MM5 and MM8B) overexpressing c-Myb were injected into the mammary 
fat pads (m.f.p.) of BALB/c mice and metastasis were analyzed 24-28 days post injection (p.i.) 
(Supplementary Figure 1a). Mice bearing Myb-overexpressing tumors have significantly less 
metastatic foci in lungs compared to mock-transfected controls (Figure 1a), while liver metastasis 
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remained unchanged (Supplementary Figure 1b). When we used 4T1 cells expressing luciferase, 
we observed particularly lung metastasis that was decreased in Myb-overexpressing tumors 
(Supplementary Figure 1c). To determine whether c-Myb affects metastatic dissemination, we 
assessed the lung seeding of 4T1 cells after intravenous injection (i.v.). The clonogenic growth of 
4T1 cells isolated from lungs 24 h after i.v. injection revealed that MM5 cells produced less 
colonies compared to mock-transfected cells (Supplementary Figure 1d). To validate these 
findings we tested human breast cancer cell line MDA-MB-231, and prepared these cells with 
MYB overexpression (MYbhigh) and MYB deletion (MYB KO), respectively. Increased MYB 
expression resulted in significantly reduced lungs metastasis, but also decreased metastasis to the 
bone and to the liver (Figure 1b,c, Supplementary figure 1e). On contrary, MYB deletion caused 
overall increased metastasis in all three tissues. These data indicate that c-Myb expression in 
MDA-MB-231 breast cancer cells correlates with reduced metastasis. 
To corroborate the c-Myb involvement in metastasis, we passaged parental 4T1 cells in 
vivo and selected cells with high lung-seeding capacity (Supplementary Figure 1f). After three 
selection rounds the resulting cell line (named lung3) exhibited significantly increased lung 
seeding when compared to parental cells (wt) as determined by clonogenic assay (Figure 1d, 
Supplementary Figure 1g). In addition, m.f.p. injection of lung3 cells resulted in increased 
spontaneous lung metastasis (Figure 1e), while the tumor growth and liver metastasis was not 
affected (Supplementary Figure 1h-j). Interestingly, lung3 cells showed decreased Myb 
expression both on mRNA and protein levels (Figure 1f).  
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Low Myb expression correlates with increased expression of inflammatory response genes 
We tested the hypothesis that c-Myb drives transcriptional program preventing lung 
colonization by breast cancer cells, which is blunted in highly metastatic cells. To identify 
components of c-Myb-driven transcriptional program, we performed RNAseq of the 
complementary cell lines; Myb-overexpressing cells MM5 and lung3 cells with respective 
controls (Figure 2a). Genes that are down-regulated in MYBhigh cells and up-regulated in lung3 or 
vice versa were further analyzed. We identified a group of 12 transcripts up-regulated in MM5 
and down-regulated in lung3 cells and a group of 35 transcripts down-regulated in MM5 but up-
regulated in lung3 cells (Figure 2b). Gene ontology analysis revealed that the group with 35 
genes upregulated in lung3 cells is significantly enriched in immune/inflammatory response 
genes (Figure 2c, Supplementary Figure 2, Supplementary Tables 4, 5). However, no significant 
GO enrichment was identified in the group of transcripts up-regulated in MM5 cells. Hence, c-
Myb levels in 4T1 cells inversely correlate with specific inflammatory molecules. Nine genes of 
this inflammation-enriched set, Ccl2, Cxcl1, Cxcl5, Cxcl16, Il1a, Lcn2, Icam1, Tnfrsf9, Ikbke, 
were validated by qPCR in independent 4T1 clone overexpressing Myb MM8B (Figure 2d) and 
another mammary carcinoma cell line with basal-like characteristics, E0771.LMB. Transient Myb 
overexpression in E0771.LMB cells resulted in down-regulation of Ccl2, Cxcl1, Cxcl5, Cxcl16, 
Il1a, Lcn2, Icam1, Ikbke mRNA levels (Figure 2e). Taken together, these data indicate that c-
Myb regulates lung metastasis through suppression of an inflammatory signature of tumor cells.  
 
c-Myb suppresses Ccl2 expression in tumor cells and thereby inhibits lung metastasis 
To validate the effect of Myb expression on inflammatory signature, we selected Ccl2 
chemokine, which has been previously shown to promote metastasis in various cancers.16-19 MM5 
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and MM8B cells showed significantly reduced while lung3 cells significantly increased amounts 
of Ccl2 in the conditioned media when compared to controls (Figure 3a). Of note, Ccl2 
expression was attenuated also upon transient Myb induction in 4T1 cells (Supplementary Figure 
3a). To test whether c-Myb is directly responsible for suppression of the Ccl2 expression, we 
analyzed the regulatory regions of the Ccl2 gene for potential Myb-binding sites (MBSs). Six 
MBSs were identified in proximal region 2000 bp upstream of the transcription starting site 
(Figure 3b), and ChIP assays were performed to examine the c-Myb occupancy of these sites. We 
prepared 4T1-derived clone C11 overproducing c-Myb with C-terminal Myc-tag for the ChIP 
assay (Supplementary Figure 3b). Three different non-overlapping amplicons showed a c-Myb 
binding to the endogenous Ccl2 promoter (Figure 3c and Supplementary Figure 3c). In addition, 
ChIP assay in MDA-MB-231 cells showed binding of both endogenous and exogenous c-Myb to 
human CCL2 promoter. Anti-Myb antibody precipitated a sequence spanning two MBSs 
(hCCL2) upstream TSS of human CCL2, but not a control region without MBSs (hCCL2_neg) in 
wt and MYBhigh (M5) cells (Supplementary Figure 3d). These data indicate that c-Myb directly 
modulates the expression of Ccl2.  
To validate that Myb expression affects Ccl2 production and metastasis, we generated 
stable transfectants of E0771.LMB cells expressing exogenous c-Myb (MYBhigh) (Supplementary 
Figure 3e) and these cells produced lower amounts of Ccl2 compared to controls (Figure 3d). 
Intravenous injection of MYBhigh E0771.LMB resulted in attenuated lung metastasis when 
compared to parental cells (Figure 3e). Of note, c-Myb overexpression in two independent clones 
of MDA-MB-231 cells also resulted in reduced secretion of CCL2 (Supplementary Figure 3f). 
Next, we tested whether down-regulation of Ccl2 affects lung colonization of 4T1 cells. Stable 
Ccl2 knock-down in 4T1 cells (shCcl2) resulted in reduced Ccl2 production (Supplementary 
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Figure 3g). Significantly less lung metastasis were observed upon m.f.p. injection of 4T1 shCcl2 
cells when compared to sh-scrambled control cells (scRNA) (Supplementary Figure 3h).  
The reduced capacity of Myb-expressing tumor cells to form lung metastasis can be linked 
to impaired tumor cell extravasation, which is known to be dependent on Ccl2.17,20 Therefore, we 
tested the capacity of tumor cells to migrate through endothelial cells in vitro. Trans-endothelial 
migration (TEM) of mock 4T1 cells through endothelial cell monolayers was enhanced by 
monocytes as observed previously. However; the migration of all 3 Myb overexpressing 4T1 
clones MM5, MM8B, and C11 was impaired, while lung3 cells expressing lower levels of Myb 
showed enhanced TEM capacity (Figure 3f). Next, we assessed whether c-Myb interferes with 
efficient TEM by data-mining in microarray databases (GSE44552). Human BC cell lines known 
to be active in TEM21 express rather low endogenous MYB RNA levels compared to TEM-
negative cell lines (Figure 3g). Further analysis of inflammatory signature genes in this dataset: 
CCL2, CXCL1, CXCL2 (human orthologue of murine Cxcl1), CXCL6 (human orthologue of 
murine Cxcl5), IL1A, ICAM1, IKBKE, LCN2, TNFRSF9; showed a reduced expression in Mybhigh 
TEM-negative cell lines, while in TEM-positive BC cells an induction of a specific inflammatory 
signature was detected. These data support the inverse correlation between c-Myb and Ccl2 
expression and its effect on lung metastasis. 
 
c-Myb inhibits tumor cell extravasation in an endothelial Ccr2-dependent manner 
To test whether Ccl2 is sufficient to rescue TEM of Myb-overexpressing 4T1 cells we 
applied conditioned medium (CM) from mock or MM5 cells. Mock CM significantly promoted 
TEM of MM5 cells; while the CM from MM5 cells had a little effect (Figure 4a). Furthermore, 
exogenous Ccl2 expression in Myb-overexpressing 4T1 cells also rescued TEM (Figure 4b, 
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Supplementary Figure 4a), indicating that c-Myb inhibits trans-endothelial migration of tumor 
cells through down-regulation of Ccl2. To test whether the reduced capacity of Myb-
overexpressing tumor cells to migrate through the endothelial cells can be observed also in vivo, 
we intravenously injected MM5 cells and analyzed lung vascular permeability. Indeed, MM5 
cells failed to induce pulmonary vessel permeability when compared to mock-transfected controls 
(Figure 4c, Supplementary Figure 4b). Since the failure of tumor cells to induce vascular 
permeability results in impaired cancer cell extravasation20, these findings indicate that c-Myb 
expression impairs the tumor cell extravasation and thereby lung colonization. 
To identify Ccl2-responsive cells involved in TEM, we first determined Ccr2 expression 
in 4T1 cells, lung and liver ECs and monocytes. Ccr2 was not expressed in 4T1 cells 
(Supplementary Figure 4c); that is in agreement with previous reports.22 Monocytes isolated 
either from wt or Ccr2-/- mice promoted TEM of 4T1 cells to the same level (Figure 4d). 
However, there was no monocyte-induced TEM observed on lung ECs derived from Ccr2-/- mice 
(Figure 4e). Inflammatory mediators are known to disrupt endothelial integrity by the Src kinase 
activation.23,24 To test whether endothelial cells respond directly to Ccl2, we stimulated ECs 
derived from lungs and liver. A time-dependent increase in p-Src (Y316) was observed in wt lung 
ECs, but not in Ccr2-/- ECs (Figure 4f), while no changes were observed in liver ECs irrespective 
of Ccr2 expression.  
To test whether c-Myb modulation in the primary tumor affects the formation of lung and 
liver metastatic niche, we analyzed leukocyte recruitment to the metastatic sites in mice m.f.p.-
injected with 4T1 cells at 15 and 22 days p.i. We observed an increased recruitment of leukocytes 
(CD45+) at day 22, but no significant difference between mock and Myb-overexpressing (MM5, 
MM8B) tumors (Figure 4g). The composition of leukocytes recruited to the lungs and liver, 
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including myeloid cells (CD11b+), inflammatory monocytes (Ly6Chi), granulocytes (Ly6G+), 
macrophages (CD64+), was not different (Figure 4g, Supplementary Figure 4d).  
 
Low MYB/high inflammatory signature is associated with poor prognosis and increased 
risk of BC lung relapse 
High MYB expression is associated with good prognosis for BC patients.10,11 Our meta-
analyses using KM-Plotter confirmed that high MYB levels are linked with longer overall survival 
and lower risk of relapse or occurrence of distant metastasis (Supplementary Figure 5a). High 
MYB levels are generally found in less aggressive luminal subtypes (Figure 5a, Supplementary 
Figure 5b) that tend to metastasize to the bone rather than to the lungs or brain.25-27 To determine 
whether MYB modulates metastasis, we first calculated correlations between the expression of 
MYB and inflammatory signature genes within and across molecular subtypes of BCs in several 
independent publically available datasets (Figure 5b, Supplementary Table 3). Significant inverse 
correlations of MYB with CCL2, CXCL1, CXCL2, CXCL6, LCN2, were found in all six cohorts 
and in 5 cohorts additionally for ICAM1 across subtypes. Importantly, CCL2 mRNA levels were 
inversely correlated with MYB expression also within basal and luminal subtype from 3 datasets. 
To verify these data we evaluated c-Myb and Ccl2 protein levels in a cohort of 68 BCs patients 
by IHC. Estrogen receptor (ER) expression was significantly associated with c-Myb expression, 
while there was a trend towards negative association with a number of Ccl2-positive cells (Figure 
5c). When the patient samples were analyzed according to the ER status, a significant inverse 
correlation between MYB and CCL2 was found within ER- group (n=19).  
Next, we performed survival meta-analysis to test the probability of distant metastasis-
free survival (DMFS), relapse-free survival (RFS) and overall survival (OS) in BCs stratified 
11 
 
according to the expression status of the signature genes (CCL2, CXCL1, CXCL2, CXCL6, 
CXCL16, ICAM1, IL1A, TNFRSF9, LCN2, IKBKE) along with MYB (inversed). A significant 
correlation was observed between the signature expression and shorter survival outcome (Figure 
6a, Supplementary Figure 6a). Importantly, the risk of distant metastasis remained increased in 
patients within basal (HR=1.94, p=0.073) or luminal group (HR=2.13, p=0.008) with a low 
MYB/high inflammatory signature status. Next, we analyzed datasets GSE2603 and GSE12276 
for lung metastasis-free survival based on MYB expression using cohorts of primary tumors from 
BC patients with known site of relapse. We found a significant association between high MYB 
expression and longer lung-relapse free survival (HR=0.2215, p<0.0001; and HR=0.2464, 
p=0.0196) that remained significant also in ER-negative tumors (HR=0.1683, p=0.0086) (Figure 
6b). 
To determine whether c-Myb-repressed inflammatory signature correlates with lung 
relapse we used Sample Level Enrichment Analysis (SLEA).28 We observed a significant 
correlation between inflammatory signature genes and the risk of lung relapse (HR=3.795, 
p<0.0001; and HR=6.704, p<0.0001) even within the ER-negative group (HR=5.965, p=0.0005) 
(Figure 6c). Similar results were obtained with other independent cohorts (Fig. S6B). The 
analysis of the GSE12276 dataset for site-specific distant metastasis relapse showed that neither 
high MYB levels, nor inflammatory signature was associated with the risk of bone or liver/lymph 
node metastases (Figure 6c). When we compared MYB expression in primary BCs (GSE2603 and 
GSE12276 datasets) with known site of relapse and in BCs metastases (GSE11078), we observed 
lower MYB expression in tumors metastasizing to the lungs when compared to metastasizing 
tumors to other tissues (Supplementary Figure 6c). Overall these data show that the identified 
inflammatory signature, together with the MYB expression, predicts lung metastasis relapse in BC 
patients independently of the ER status.  
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Discussion 
TF c-Myb was described to have oncogenic and tumor suppressor activities in BCs.8-11,29 
Clinical data have unanimously associated MYB with a good prognosis for BC patients 10-12 that is 
agreement with our findings. There is only one recent study indicating the opposite tendency in 
one dataset;30 however, we could not reproduce these results by analysis of the same dataset. 
Here we showed that MYB expression in human BC tumor cells predicts a low risk of lung 
relapse. Low MYB expression is commonly associated with ER-negative BCs 25 and these tumors 
are known to preferentially colonize lung tissue when compared to ER-positive BCs.26,27 
Consequently, high MYB marks BCs with longer lung-metastasis-free survival. Importantly, our 
data show that the association between MYB and the lung-metastasis-free survival is sustained 
within ER-negative cohort of BC patients, emphasizing c-Myb as an ER-independent risk factor 
for lung metastasis. We postulate that c-Myb expression, albeit potentially important for 
proliferation and early tumorigenesis8,9,29, has a negative impact on lung colonization of BCs. 
TF c-Myb is a transcription regulator that is involved in regulation of cell growth and 
survival acts in a context-dependent manner.4,6,7 In our study the modulation of Myb expression 
did not alter cell proliferation or the cell cycle (Supplementary Figure 7a,b). Interestingly, higher 
Myb expression makes cells to be more resistant to chemotherapy (Supplementary Figure 7c), as 
previously observed.8,31 Myb expression was recently also linked to metastatic progression in 
pancreatic and breast cancer models.30,32 While c-Myb may act differently depending on the 
tissue origin32, there is discrepancy in breast cancer between our data and the previously 
published data.30 This may be due to a different subline (MDA-MB-231 BM) used in the report 
of Li et al30, while we were using the parental MDA-MB-231 cell line. Several genes previously 
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identified as Myb-responsive11 were also confirmed in this work (Supplementary Figure 8). To 
define the transcriptional module responsible for lung metastasis suppression in mammary 
tumors, we compared transcriptomes of two complementary cell populations of lung metastasis-
proficient and -deficient 4T1 cells. Increased c-Myb expression in lung-deficient cells suppressed 
genes involved in inflammation and immune-responses. Inflammatory mediators, including 
cytokines, were shown to directly promote metastasis through: increased vascular permeability 
and tumor cell survival in the circulation, mediating the immune escape and outgrowth at 
secondary sites, particularly in the lungs.17,18,33,34 Although causal interdependence between 
inflammation and cancer progression has long been established, unveiling the molecular 
mechanisms from a TF to a specific inflammatory circuit that modulates metastatic seeding is 
highly relevant for prospective therapy application.  
Despite a variation in MYB expression among BCs subtypes, several inflammatory genes 
within the c-Myb-repressed module are associated with ER-negative status of BCs: e.g. LCN2 is 
highly expressed in ER-negative BCs 35, ICAM1 is overexpressed in human triple-negative BCs 
36, CXCL1, CXCL3, CXCL5, CXCL6, and IL-8 are highly present in ER-negative tumors.37 Of 
note, a unique subgroup of ER+ BCs that express high levels of c-Myb and low level of innate 
inflammatory genes has been identified.11 Our findings indicate that c-Myb-initiated 
transcriptional program in ER-negative BCs results in blunted inflammatory response thereby 
limiting lungs metastasis while enabling metastasis in other organs.  
TF c-Myb can repress expression of approximately half of its direct targets, despite being 
usually considered as a trans-activator.38 However, the repressing function of c-Myb remains 
poorly understood and is likely target-specific.6,7 Here we provide evidence that c-Myb 
expression suppresses lung metastasis in two mammary mouse models. Thus we postulate that 
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both direct binding of c-Myb to the regulatory elements of the inflammatory genes, demonstrated 
for Ccl2, together with additional indirect effects contribute to the c-Myb-repressed 
transcriptional program in a gene-specific fashion. How the c-Myb represses all inflammatory 
genes in the identified signature in vivo remains to be defined.  
Ccl2 is one of the inflammatory mediators repressed by c-Myb, which has been identified 
as a prominent tumor- and metastasis-promoting factor in BCs.18,19,39,40 Previously we 
demonstrated that endothelial Ccr2 expression in the lungs is required for tumor cell 
extravasation and E-selectin-dependent monocyte recruitment required for metastasis.17,20 In line 
with these results our current data show that suppression of tumor-derived Ccl2 by c-Myb 
impairs TEM of BC cells due to missing endothelial engagement while the recruitment of 
myeloid-derived cells remained unaffected. These findings suggest that enhanced c-Myb levels 
diminish the ability of circulating BC cells to activate pulmonary endothelium, thereby inhibits 
lung metastasis (Figure 6d). 
Extravasation into the pulmonary tissue requires specific functions for breaching the tight 
capillary walls, while liver is relatively compliant to TCs extravasation owing to the fenestrated 
endothelium.41,42 Interestingly, we found that the c-Myb-dependent inhibition of TEM and 
metastasis is tissue-specific. Liver is permissive for Myb-overexpressing TCs that is in contrast to 
the lungs. We observed that liver ECs do not respond to recombinant Ccl2 stimulation by Src 
activation when compared to lung ECs. This data indicate that tumor-derived factors may elicit 
tissue-dependent responses promoting metastasis.   
In conclusion, the inflammatory response controlled by c-Myb determines the metastatic 
competency of BCs cells. The identified inflammatory signature improves the identification of 
high-risk patients for lung relapse in majority of analyzed datasets compared to a single MYB 
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assessment. Importantly, these markers predict lung relapses in BC patients irrespective of ER 
expression. Inhibition of the c-Myb-driven paracrine inflammatory axis may improve targeting of 
tumor cells that are inaccessible to standard anti-proliferative therapy and thereby lower the 
incidence of metastasis. 
 
 
Material and Methods 
Cell culture 
Cell lines 4T1 and MDA-MB-231 were purchased from American Type Culture Collection and 
were cultured RPMI-1640/10% FCS. 4T1 and MDA-MB-231 cells with constitutive c-Myb 
overexpression (MYBhigh) were previously described.15 E0771.LMB cells were kindly provided 
by Dr. Robin Anderson (University of Melbourne, Australia)43 and were cultured in DMEM/10% 
FCS. E0771.LMB cells overexpressing Myb were prepared by transfection with pcDNA3.Myc-
tag-Myb using Lipofecamine® LTX (Life Technologies) and selected with 500µg/ml G418. 
Stable knock-down clones of Ccl2 in 4T1 cells were generated by lentiviral infection with a two 
MISSION shRNAs targeting Ccl2 in pLKO.1 or non-mammalian shRNA control vector (both 
Sigma) and selection with 1.5μg/ml puromycin. 4T1 lung3 cells were prepared by three rounds of 
in vivo passage of wt cells, where lung tissues were harvested 24 hours later, and tumor cells 
grew under selection of 6-thioguanine (60μM).  
Generation of MDA-MB-231 MYB knock-out cell line with CRISPR/Cas9 
Guide RNA (gRNA) sequences for CRISPR/Cas9 were designed at CRISPR design web site 
(http://crispr.mit.edu/). The 25-bp forward and reverse oligonucleotides (Table S1) comprising 20 
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bp MYB-target sequence and Esp3I sticky ends were annealed and inserted into the 
lentiCRISPRv2 plasmid (Addgene 52961, Cambridge, MA) digested with Esp3I enzyme. 
Similarly, oligonucleotides comprising GFP-target sequence (Table S1) were used for derivation 
of a control plasmid. All plasmids were sequenced. MDA-MB-231 cells were transfected with 
lentiCRISPRv2 plasmids using Lipofectamine LTX, selected under puromycin (1μg/ml) for 2 
weeks. Single-cell colonies were expanded for DNA extraction, protein extraction, and 
cryopreservation. PCR primers spanning potential sites of mutation were designed (Table S1), 
mutations were confirmed by Sanger sequencing and the efficiency of MYB knock-out was 
verified by immunoblotting.  
 
Mice 
Animal experiments were performed according to the guidelines of the Swiss Animal Protection 
Law, and approved by Veterinary Office of Kanton Zurich. Female mice (6-9 weeks old) 
BALB/c, NOD scid gamma (NSG), C57BL/6, and Ccr2 deficient mice (Ccr2-/-) were purchased 
from The Jackson Laboratory. 
 
Metastatic assay and lung seeding experiments 
4T1 cells (100’000 cells) in HBSS:Matrigel (1:1) were orthotopically injected into a mammary 
fat pad (m.f.p.) of a BALB/c mice and metastasis was analyzed after 24-28 days. MDA-MB-231 
cells (2’000’000) were injected in m.f.p. of NSG mice and metastases were evaluated after 42 
days. E0771.LMB (600’000) cells were intravenously injected (i.v.) in the tail vein of C57BL/6 
mice and lung metastatic foci were analyzed after 17 days. For lung seeding experiments, 
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300’000 cells were i.v. injected and perfused lungs after 24 hours were digested with collagenase 
A/D (Sigma), passed through 40μm cell strainers, and cells were grown in presence of 6-
thioguanine (60μM) for 10 days. Clonogenic growth was assessed after fixation with 4% PFA 
and 0.04% crystal violet staining.  
 
Flow cytometry analysis of lung and liver tissues 
The lungs of 4T1-tumor bearing mice were perfused, minced and digested in Collagenase D and 
A (2 mg each, Roche) for 1 hour at 37°C. A single-cell suspension using 40μm cell strainers was 
prepared, erythrocytes lysed. Cells were resuspended in staining buffer with Fc block 
(eBioscience), incubated on ice for 10 min, followed by staining with following antibodies: 
CD45-PB, CD11b-BV510, CD64-PE, Ly6C-APC, Ly6G-PerCP-Cy5.5 (all from BD) for 30 min. 
Data were collected with CountBright absolute counting beads (Life Technologies) using a 
FACSCanto (BD) and analyzed by FlowJo software (FlowJo, LCC).  
 
Vascular permeability assay 
Lung vascular permeability was determined with Evans blue assay 17.  
 
RNA isolation and quantitative real-time PCR 
Total RNA was isolated with RNeasy Mini kit (Qiagen) and cDNA was prepared with 
Omniscript RT Kit (Qiagen). Real-time PCR was performed with KAPA SYBR Fast Master mix 
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(KAPA Biosystems) with intron-spanning primers (Table S1) using the LightCycler 480 (Roche) 
and data were normalized to Gapdh.15 
 
Cytokine assay 
Supernatants of cells cultured for 48 hours were collected and the amount of Ccl2 was assessed 
using the Cytometric Bead Array kit (BD Biosciences).  
 
Isolation and stimulation of primary endothelial cells  
Pulmonary and liver endothelial cells (ECs) were isolated using a positive immuno-magnetic 
selection as described previously.17 Seven days after isolation, cells were stimulated with murine 
recombinant (mr) IL1β (40 ng/ml, R&D Systems) for 2 hours, followed by treatment with 
mrCcl2 (100 ng/ml, R&D Systems) for indicated time. ECs were then lysed and proteins 
analyzed by immunoblotting. 
 
Trans-endothelial migration assay 
Trans-endothelial migration assay was performed as described previously.17 Alternatively, tumor 
cells were seeded in the upper chamber in conditioned media. 
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Immunoblotting 
Tumor cell lysis and Western blot analysis were performed as described.15 Primary ECs were 
lysed with lysis buffer (20mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 
protease/phosphatase inhibitors) for 30 min on ice and supernatants were resolved by SDS-
PAGE. Following antibodies were used: Myb (05-175, Millipore), p-Src (Tyr416) (6943S, Cell 
Signaling), Myc-Tag (9B11, Cell Signaling) and FLAG (F3165, Sigma). The membranes were 
probed with β-actin (A5060, Sigma) or α-tubulin (T9026, Sigma) antibodies for sample loading 
controls. 
 
Chromatin immunoprecipitation (ChIP) analysis 
Forty millions of 4T1 cells overexpressing Myc-tagged Myb (C11) and wt cells were cross-linked 
with 1% methanol-free formaldehyde for 10 min, followed by neutralization with glycine (final 
conc. 0.125M). Cells were lysed and chromatin was sheared to ∼400 bp fragments using the 
Bioruptor Plus sonicator (Diagenode). ChIP assays were performed using Imprint Chromatin 
immunoprecipitation kit (Sigma) with anti-Myc-Tag antibody (9B11, Cell Signaling) and isotype 
control (mouse IgG). DNA was analyzed by qPCR using three primer pairs flanking different 
Myb binding sites (MBSs; 118 bp, 853 bp, and 981 bp upstream transcription start site, TSS) 
within the Ccl2 promoter region. MBSs were identified using TFSEARCH and ConSite 
(http://consite.genereg.net). TSS of the Gapdh gene (Gapdh_TSS) was used as a negative control. 
TSS of a known c-Myb target gene Gata3 was used as positive control.44 Immunoprecipitated 
chromatin fragments from C11 and wt cells were used as templates for conventional PCR. The 
regions in the Ccl2 promoter harboring the MBSs were PCR amplified. Non-immunoprecipitated 
chromatin was used as an input. ChIP assay with human MDA-MB-231 cells (wt and MYB-
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overexpressing M5) was performed similarly with anti-Myb antibody (ab45150, Abcam) and 
rabbit IgG. Primers flanking two MBSs (677 bp and 723 bp upstream TSS) and negative control 
region without MBSs were used. All primer sequences are in listed the Table S1. 
 
Immunohistochemistry 
The study group included 68 BC patients undergoing surgical treatment at Lviv Regional 
Oncological Center between 2013-2015. Immunohistochemical (IHC) detection of c-Myb, CCL2, 
and ER was performed on formalin fixed paraffin embedded tissues of primary tumors using the 
following antibodies: c-Myb (EP769Y, Abcam), CCL2 (PA5-34505) and ER (SP1; MA5-14501; 
both from Thermo Fisher). 
 
RNA-sequencing and functional enrichment analysis  
RNA quality control, library preparation (TruSeq RNA Kit), sequencing on an Illumina HiSeq™ 
2500, and data pre-processing were performed at the Functional Genomics Center Zurich 
(FGCZ). NGS data analysis system developed by the FGCZ bioinformatics, supporting selected 
open source, NGS data analysis packages, along with SUSHI data analysis was used.45 Reads 
were aligned using the STAR aligner 46 of at least 30bp matching; and acceptance at most 5 
mismatches, and at most 5% of mismatches was used. Read alignments were only reported for 
reads with less than 50 valid alignments (Table S2). The mouse genome build and annotation 
from Ensembl (GRCm38) were used as the reference. Expression counts were computed using 
the Bioconductor package Genomic Ranges.47 Differential expression was computed using the 
Edger package.48 Only transcripts with a fold change >1.5 and an uncorrected p-value <0.01 
between mock and MYBhigh cell lines, and between wt and lung3 cell lines were considered. We 
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subtracted RNAs differentially expressed in mock-transfected and parental (wt) cells, and 
analyzed overlapped transcripts between subsets upregulated in lung3 and downregulated in 
MYBhigh, and vice versa. The set of enriched genes (35 RNAs) was analyzed using DAVID 
Bioinformatics Resources for functional classification.49 GO terms with FDR<0.05 were 
reported.  
 
Correlation analysis 
We used Oncomine (www.oncomine.org), Medisapiens (ist.medisapiens.com) and NCBI GEO 
databases to assess the differential expression of MYB, CCL2, CXCL1, CXCL2, CXCL6, 
CXCL16, ICAM1, IL1A, TNFRSF9, LCN2, IKBKE mRNA in human BCs. Pearson correlations 
were calculated with the GraphPad Prism software (version 6.07). Six independent datasets were 
used (accession numbers: EGAS00000000083, GSE25066, GSE22358, GSE22226, GSE12276, 
GSE20685), results in Table S3.  
 
Survival analysis 
Kaplan–Meier plots representing the probability of distant metastasis free survival (DMFS), 
relapse-free survival (RFS) and overall survival (OS) in BCs stratified according to the 
expression status of the signature genes (CCL2, CXCL1, CXCL2, CXCL6, CXCL16, ICAM1, 
IL1A, TNFRSF9, LCN2, IKBKE) and MYB (inversed) were calculated with KM plotter 
kmplot.com50. Patients were stratified according to median expression of indicated genes. The 
log-rank test was used to assess the significance of the correlation between gene(s) expression 
and shorter survival outcome. 
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Kaplan–Meier curves for site-specific distant metastasis-free survival based on MYB expression 
were calculated with the GraphPad Prism (version 6.07) using cohorts of GSE260351 and 
GSE1227652 of BC patients with known site of relapse. 
The correlation between c-Myb-repressed inflammatory signature and lung relapse was analyzed 
using Sample Level Enrichment Analysis (SLEA) with datasets GSE2603 and GSE1227628. 
Gitools (www.gitools.org) were used to calculate the Z-score indicating the transcriptional status 
of the gene set in each sample. Analysis of the site specific-relapse free survival of patients was 
performed using the GraphPad Prism (version 6.07). 
 
Statistics 
Statistical analysis was performed with the GraphPad Prism software (version 6.07). All data are 
presented as mean ±SD and were analyzed with Mann-Whitney test unless stated otherwise.  
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Figure legends 
Figure 1. c-Myb inhibits lung metastasis of BC cells. (a) Number of metastatic foci in lungs of 
tumor-bearing BALB/c mice 28 days after m.f.p. injection of 4T1 cells: mock or Myb-
overexpressing clones MM5 and MM8B (2 independent experiments). Representative images of 
lungs fixed in Bouin’s solution. (b-c) Metastasis of MDA-MB-231 cells upon m.f.p. injection 
into NSG mice and terminated at day 42, using MDA-MB-231 cells: transfected with empty 
vector (mock), expressing human MYB (MYBhigh), transfected with control gRNA (Scr); and 
deficient in MYB expression (MYB KO). (b) Quantification of lung metastasis with 
representative H&E stained lung sections; scale bar = 50µm. (c) Quantification of bone 
metastasis incidence and amounts with representative H&E stained bone sections; scale bar = 
100µm. (d) Lung seeding of parental = wt, and lung3 cells. Number of colonies formed by 4T1 
cells lodged in lungs 24 hours p.i (n=3). (e) Quantification of lung metastatic foci from BALB/c 
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mice bearing 4T1 wt and lung3 tumors 28 days after m.f.p. injection (2 independent 
experiments). (f) Immunoblot analysis of c-Myb expression in parental (wt), and lung3 subline of 
4T1 cells. Expression levels of Myb mRNA in the lung3 subline analyzed by qPCR and 
normalized to Gapdh, showed as relative values to parental cells (n=5). *; p<0.05; **; p<0.01; 
***; p<0.001. 
 
Figure 2. c-Myb represses immune/inflammatory response genes in BC cells. (a) Strategy of 
RNAseq analysis to identify overlapping genes up/down-regulated in 4T1 MYBhigh and lung3 
cells. (b) Heat map of 47 genes identified as induced/repressed in 4T1 MYBhigh and lung3 cells 
(fold change>1.5, p<0.01). (c) DAVID analysis software was used to find the Gene Ontology 
(GO) terms that were significantly enriched (FDR<0.05) in a 35 gene set highly expressed in 
lung3 and suppressed in MYBhigh cells (BP, biological process; MF, molecular function; CC, 
cellular compartment). (d) Expression levels of selected mRNAs in 4T1 MYBhigh clones and the 
lung3 subline were analyzed by qPCR, normalized to Gapdh and displayed as relative values to 
parental cells (n=3). *; p<0.05; **; p<0.01. (e) Expression levels of selected mRNAs after 
transient (48 hours) Myb overexpression in E0771.LMB cells by qPCR, normalized to Gapdh and 
displayed as relative values to mock-transfected E0771.LMB cells (n=3). 
 
Figure 3. c-Myb suppresses Ccl2 expression and inhibits tumor cell metastasis and TEM. 
(a) Ccl2 protein levels in the tumor cell conditioned media were normalized to total protein 
content (n=3). (b) Schematic representation of the promoter region of murine Ccl2 gene on 
chromosome 11. The potential c-Myb binding sites (MBSs, identified by TFSEARCH and 
30 
 
ConSite, http://consite.genereg.net), the regions amplified after ChIP (primer pairs: red, blue, and 
green arrows) are depicted. (c) ChIP assays were performed with anti-Myc-Tag antibody or non-
specific mouse IgG in 4T1 cells transfected with Myc-tagged-Myb (C11) and wt cells (n=3). 
Three primer sets spanning different MBSs were used for qPCR amplification and data are shown 
as percentage of input, unpaired t-test. Gapdh was used a negative control; Gata3 as a positive 
control. (d) Ccl2 protein levels in the E0771.LMB tumor cell conditioned media: wt, mock-
transfected controls, MYBhigh pool and MYBhigh C2 normalized to total protein content (n=3, 
unpaired t-test). (e) Quantification of lung metastasis in mice i.v. injected with E0771.LMB cells 
17 days p.i. (2 independent experiments) (f) Transmigrated 4T1 cells through primary lung ECs 
in the absence or presence of monocytes after 16 hours of co-culture. (3 independent 
experiments) (g) Expression-based clustering of BC cell lines (GSE44552) according to the TEM 
activity. Signature genes expression levels as determined by microarrays are visualized in a heat-
map. Hierarchical clustering by Gitools is shown in shades of blue. *; p<0.05; **; p<0.01; ***; 
p<0.001. 
 
Figure 4. TEM of tumor cells is dependent on lung endothelial Ccr2 expression. (a) TEM of 
MM5 cells untreated (-) or stimulated with conditioned medium (CM) from mock or MM5 cells, 
in the presence of monocytes after 16 hours. (2 independent experiments) (b) TEM of 4T1 
MYBhigh cells overexpressing Ccl2 through lung ECs in the presence of monocytes. (2 
independent experiments) (c) Quantification of Evans blue extracted from lungs of mice: 
untreated (naïve) or 24 hours p.i. with 4T1 mock and MM5 cells (n=4-6). (d) Tumor cells (4T1 
mock) transmigration through lung ECs derived from wt C57BL/6 mice in the presence of wt and 
Ccr2-/- monocytes. (2 independent experiments) (e) TEM of mock 4T1, MM5 and C11 cells 
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through Ccr2-/- lung ECs in the presence/absence of monocytes. (2 independent experiments) (f) 
Immunoblot analysis of p-Src in Ccl2-stimulated (100ng/ml) ECs derived from wt and Ccr2-/- 
mice, left. Densitometry quantification of p-Src signal (n=5), right. (g) Flow cytometry analysis 
of total leukocytes (CD45+), myeloid cells (CD45+CD11b+), granulocytes (CD45+CD11b+CD11c-
Ly6G+), and inflammatory monocytes (CD45+CD11b+CD11c-Ly6G-Ly6Chi) recruited to the 
lungs 15 and 22 days p.i. *; p<0.05; **; p<0.01; ns; not significant. 
 
Figure 5. Inversed MYB-inflammatory signature expression in human BCs. (a) Heat map 
showing expression levels of MYB and identified signature genes in human BCs (GSE22358). 
Red and blue indicate high and low mRNA expression levels, respectively. (b) Significant 
correlations between mRNA expression of MYB and CCL2 in the same dataset of BCs samples as 
in A and stratified according to the molecular subtype (basal, luminal A). (c) Representative IHC 
stainings of human BCs for c-Myb, Ccl2, ER (left). Kendall’s Tau correlation between ER, CCL2 
and c-Myb detection analyzed in a group of 68 BC patients, and in ER+ and ER- patients. *; 
p<0.05.   
 
Figure 6. Inflammatory signaling that is suppressed by MYB is required for lung 
metastasis. (a) Meta-analyses of BCs patients available on KMplot.com representing the 
probability of distant metastasis free survival in BCs stratified according to the expression status 
of the signature genes (CCL2, CXCL1, CXCL2, CXCL6, CXCL16, ICAM1, IL1A, TNFRSF9, 
LCN2, IKBKE and inversed MYB). The log-rank test P value reflects the significance of the 
correlation between inflammatory gene signature high/MYB low and shorter survival outcome. b-
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c) Kaplan–Meier plots showing lung metastasis-free, bone metastasis-free and other metastasis-
free (liver/LN) survival of BCs patients from datasets: GSE260351 and GSE1227652, respectively. 
Survival analysis based on MYB expression (b) and based on signature enrichment (defined in A) 
as determined by z-score (c). Signature enriched = samples with significant up-regulation of the 
signature; signature not-enriched = the rest of samples (d) Model of the Myb-repressed 
inflammatory circuit during pulmonary metastasis.  
 






